Guided Therapeutics Expands China Reach with New Distribution Deal

NEW YORK, NY – November 19, 2025

Expanding Access to Cervical Cancer Screening

Guided Therapeutics, Inc. has announced an initial $200,000 supply agreement with Yuanshuo Medical Instruments Corporation (YMIC), a Chinese medical device distributor. This partnership expands the company’s presence in China, building on an existing relationship with Hangzhou Dongye Medical Technology Company, Ltd. (HDMT). The agreement signals a strategic focus on the massive Chinese market, where access to advanced cervical cancer screening remains a critical public health challenge.

Cervical cancer is a significant health concern in China, accounting for a substantial portion of global cases. While the country has made strides in implementing national screening programs, coverage and accessibility continue to be areas for improvement, particularly in rural regions. The demand for rapid, non-invasive screening tools is growing, and Guided Therapeutics aims to fill that gap with its LuViva Advanced Cervical Scan. “There's a clear need for innovative screening solutions in China,” notes one industry analyst. “Anything that can increase accessibility and early detection rates is a positive development.”

Navigating the Chinese Market

The partnership with YMIC will allow Guided Therapeutics to reach a wider audience in Jiangsu Province, a region with a population of over 85 million. YMIC’s distribution network and established relationships with healthcare providers are essential for penetrating this large market. “Having a strong local partner is crucial for success in China,” states a source familiar with the Chinese medical device landscape. “Navigating regulatory requirements, building trust with hospitals, and managing logistics can be complex.”

This deal is particularly noteworthy given LuViva’s regulatory status. Unlike in the United States, where it remains an investigational device, LuViva has received approval from China's National Medical Products Administration (NMPA) for commercial sale. This allows Guided Therapeutics to generate revenue in China while it continues to pursue FDA approval in the U.S. The ability to generate revenue from the Chinese market is a critical lifeline for the company, which has historically faced financial challenges.

Financial Hurdles and Future Prospects

Despite the positive momentum, Guided Therapeutics faces significant financial hurdles. The company has consistently reported net losses and relies heavily on capital raises and strategic partnerships to fund its operations. As of the most recent quarterly filing, the company reported a tight liquidity position, with limited cash reserves and a substantial working capital deficit. “The company’s ability to sustain operations depends on its ability to secure additional funding and generate sufficient revenue,” explains an investor following the company. “The Chinese market is a key part of that strategy.”

The $200,000 initial order from YMIC represents a welcome boost for the company, but it is just the first step. To achieve long-term financial viability, Guided Therapeutics needs to demonstrate consistent revenue growth and expand its market share. The company is also focused on securing additional distribution agreements and exploring potential partnerships with other healthcare providers. “Expanding the reach of LuViva is paramount,” one company insider shares. “We're confident that our technology can make a meaningful impact on women’s health globally.”

The company’s ability to successfully navigate the Chinese market will be closely watched by investors and industry analysts. While the regulatory environment is favorable, competition is fierce, and building a sustainable business requires careful planning and execution. The success of the YMIC partnership, combined with the existing relationship with HDMT, will be critical for determining the company’s future prospects.

The firm continues to pursue FDA approval in the US, and positive results from clinical trials will unlock a significantly larger market opportunity. For now, the focus remains on expanding its presence in China and building a strong foundation for long-term growth.